-DOCSTART- -X- O
The -X- _ O
most -X- _ O
effective -X- _ O
drugs -X- _ O
available -X- _ O
to -X- _ O
treat -X- _ O
influenza -X- _ O
are -X- _ O
neuraminidase -X- _ O
( -X- _ O
NA -X- _ O
) -X- _ O
inhibitors -X- _ O
, -X- _ O
which -X- _ O
provide -X- _ O
important -X- _ O
additional -X- _ O
measures -X- _ O
for -X- _ O
the -X- _ O
control -X- _ O
of -X- _ O
influenza -X- _ B-Patient
virus -X- _ I-Patient
infections. -X- _ I-Patient
However -X- _ O
, -X- _ O
since -X- _ O
the -X- _ O
emergence -X- _ O
of -X- _ O
NA -X- _ O
inhibitor-resistant -X- _ O
viruses -X- _ O
may -X- _ O
compromise -X- _ O
the -X- _ O
clinical -X- _ O
utility -X- _ O
of -X- _ O
this -X- _ O
class -X- _ O
of -X- _ O
anti-influenza -X- _ O
agents -X- _ O
, -X- _ O
it -X- _ O
is -X- _ O
very -X- _ O
important -X- _ O
to -X- _ O
develop -X- _ O
new -X- _ O
anti-influenza -X- _ O
agents -X- _ O
which -X- _ O
target -X- _ O
a -X- _ O
different -X- _ O
region -X- _ O
in -X- _ O
NA -X- _ O
responsible -X- _ O
for -X- _ O
its -X- _ O
sensitivity -X- _ O
from -X- _ O
that -X- _ O
for -X- _ O
NA -X- _ O
inhibitors -X- _ O
and -X- _ O
could -X- _ O
be -X- _ O
used -X- _ O
to -X- _ O
treat -X- _ O
NA -X- _ O
inhibitors-resistant -X- _ O
isolates. -X- _ O
The -X- _ O
oligodeoxynucleotide -X- _ B-Intervention
D35 -X- _ I-Intervention
, -X- _ O
multimerized -X- _ O
and -X- _ O
aggregated -X- _ O
, -X- _ O
suppressed -X- _ B-Outcome
replication -X- _ I-Outcome
of -X- _ I-Outcome
influenza -X- _ I-Outcome
A -X- _ I-Outcome
viruses -X- _ I-Outcome
except -X- _ I-Outcome
A -X- _ I-Outcome
/ -X- _ I-Outcome
WSN -X- _ I-Outcome
/ -X- _ I-Outcome
33 -X- _ I-Outcome
( -X- _ I-Outcome
WSN -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
The -X- _ O
suppressive -X- _ O
viral -X- _ O
replication -X- _ O
by -X- _ O
D35 -X- _ O
depended -X- _ O
on -X- _ O
G-terad -X- _ O
and -X- _ O
multimer -X- _ O
formation. -X- _ O
The -X- _ O
range -X- _ O
of -X- _ O
the -X- _ O
suppressive -X- _ O
viral -X- _ O
replication -X- _ O
at -X- _ O
the -X- _ O
late -X- _ O
stage -X- _ O
, -X- _ O
including -X- _ O
virus -X- _ O
assembly -X- _ O
and -X- _ O
release -X- _ O
from -X- _ O
infected -X- _ O
cells -X- _ O
, -X- _ O
was -X- _ O
much -X- _ O
larger -X- _ O
than -X- _ O
that -X- _ O
at -X- _ O
the -X- _ O
initial -X- _ O
stage -X- _ O
, -X- _ O
viral -X- _ O
attachment -X- _ O
and -X- _ O
entry. -X- _ O
D35 -X- _ O
suppressed -X- _ O
NA -X- _ O
activity -X- _ O
of -X- _ O
influenza -X- _ O
A -X- _ O
viruses. -X- _ O
Furthermore -X- _ O
, -X- _ O
replacing -X- _ B-Outcome
the -X- _ I-Outcome
NA -X- _ I-Outcome
gene -X- _ I-Outcome
of -X- _ I-Outcome
A -X- _ I-Outcome
/ -X- _ I-Outcome
Puerto -X- _ I-Outcome
Rico -X- _ I-Outcome
/ -X- _ I-Outcome
8 -X- _ I-Outcome
/ -X- _ I-Outcome
34 -X- _ I-Outcome
( -X- _ I-Outcome
PR8 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
in -X- _ I-Outcome
which -X- _ I-Outcome
viral -X- _ I-Outcome
replication -X- _ I-Outcome
was -X- _ I-Outcome
inhibited -X- _ I-Outcome
by -X- _ I-Outcome
D35 -X- _ I-Outcome
at -X- _ I-Outcome
the -X- _ I-Outcome
late -X- _ I-Outcome
stage -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
NA -X- _ I-Outcome
gene -X- _ I-Outcome
from -X- _ I-Outcome
WSN -X- _ I-Outcome
, -X- _ I-Outcome
in -X- _ I-Outcome
which -X- _ I-Outcome
viral -X- _ I-Outcome
replication -X- _ I-Outcome
was -X- _ I-Outcome
not -X- _ I-Outcome
inhibited -X- _ I-Outcome
, -X- _ I-Outcome
eliminated -X- _ I-Outcome
the -X- _ I-Outcome
D35-dependent -X- _ I-Outcome
suppression. -X- _ I-Outcome
D35 -X- _ I-Outcome
showed -X- _ I-Outcome
an -X- _ I-Outcome
additive -X- _ I-Outcome
anti-influenza -X- _ I-Outcome
effect -X- _ I-Outcome
with -X- _ I-Outcome
oseltamivir. -X- _ I-Outcome
It -X- _ I-Outcome
was -X- _ I-Outcome
also -X- _ I-Outcome
effective -X- _ I-Outcome
in -X- _ I-Outcome
vivo. -X- _ I-Outcome
These -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
the -X- _ O
influenza -X- _ O
virus -X- _ O
NA -X- _ O
mainly -X- _ O
contributse -X- _ O
to -X- _ O
the -X- _ O
D35-suppressible -X- _ O
virus -X- _ O
release -X- _ O
from -X- _ O
infected -X- _ O
cells -X- _ O
at -X- _ O
the -X- _ O
late -X- _ O
stage. -X- _ O
In -X- _ O
addition -X- _ O
, -X- _ O
because -X- _ O
administration -X- _ O
of -X- _ O
D35 -X- _ O
into -X- _ O
the -X- _ O
virus-infected -X- _ O
mice -X- _ O
suppressed -X- _ O
viral -X- _ O
replication -X- _ O
and -X- _ O
weight -X- _ O
loss -X- _ O
, -X- _ O
clinical -X- _ O
application -X- _ O
of -X- _ O
D35 -X- _ O
could -X- _ O
be -X- _ O
considered -X- _ O
. -X- _ O

